Response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) differs in mouse strains and reveals a divergence in JNK signaling and COX-2 induction prior to loss of neurons in the substantia nigra pars compacta

Brain Research

Volumn 1175, Issue 1, 2007, Pages 107-116

  Boyd, Justin D ^a,b   Jang, Haeman ^a,b   Shepherd, Kennie R ^a   Faherty, Ciaran ^a   Slack, Sally ^a   Jiao, Yun ^a   Smeyne, Richard J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

COX 2; Dopamine transporter; Neuroinflammation; Oxidative stress; Parkinson's disease; Signal transduction; VMAT2

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CYCLOOXYGENASE 2; PROTEIN KINASE C; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL LOSS; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENZYME ACTIVATION; FEMALE; MALE; MESENCEPHALON; MOUSE; MOUSE STRAIN; NERVE CELL; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; SWISS WEBSTER MOUSE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; DRUG RESISTANCE; FEMALE; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MICE; MICE, INBRED C57BL; NERVE DEGENERATION; NEURONS; NEUROTOXINS; PARKINSONIAN DISORDERS; PROTO-ONCOGENE PROTEINS C-JUN; SIGNAL TRANSDUCTION; SPECIES SPECIFICITY; SUBSTANTIA NIGRA;

MUS;

EID: 34848855366     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2007.07.067     Document Type: Article

References (49)

1. Bathory G., Szuts T., and Magyar K. Studies on the melanin affinity of selegiline (deprenyl) and other amphetamine derivatives. Pol. J. Pharmacol. Pharm. 39 (1987) 195-201
2. Bezard E., Gross C.E., Fournier M.C., Dovero S., Bloch B., and Jaber M. Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Exp. Neurol. 155 (1999) 268-273
3. Burke R.E. Recent advances in research on Parkinson disease: synuclein and parkin. Neurologist 10 (2004) 75-81
4. Chiba K., Trevor A., and Castagnoli Jr. N. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 120 (1984) 574-578
5. Dauer W., and Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39 (2003) 889-909
6. Donnan G.A., Kaczmarczyk S.J., Solopotias T., Rowe P., Kalnins R.M., Vajda F.J., and Mendelsohn F.A. The neurochemical and clinical effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in small animals. Clin. Exp. Neurol. 22 (1986) 155-164
7. Faherty C.J., Raviie Shepherd K., Herasimtschuk A., and Smeyne R.J. Environmental enrichment in adulthood eliminates neuronal death in experimental parkinsonism. Mol. Brain Res. 134 (2005) 170-179
8. Fornai F., Battaglia G., Gesi M., Giorgi F.S., Orzi F., Nicoletti F., and Ruggieri S. Time-course and dose-response study on the effects of chronic l-DOPA administration on striatal dopamine levels and dopamine transporter following MPTP toxicity. Brain Res. 887 (2000) 110-117
9. Freyaldenhoven T.E., Ali S.F., and Hart R.W. MPTP- and MPP(+)-induced effects on body temperature exhibit age- and strain-dependence in mice. Brain Res. 688 (1995) 161-170
10. Gainetdinov R.R., Fumagalli F., Jones S.R., and Caron M.G. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J. Neurochem. 69 (1997) 1322-1325
11. Gainetdinov R.R., Fumagalli F., Wang Y.M., Jones S.R., Levey A.I., Miller G.W., and Caron M.G. Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice. J. Neurochem. 70 (1998) 1973-1978
12. Hamre K., Tharp R., Poon K., Xiong X., and Smeyne R.J. Differential strain susceptibility following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration acts in an autosomal dominant fashion: quantitative analysis in seven strains of Mus musculus. Brain Res. 828 (1999) 91-103
13. Hashimoto M., Hsu L.J., Rockenstein E., Takenouchi T., Mallory M., and Masliah E. alpha-Synuclein protects against oxidative stress via inactivation of the c-Jun N-terminal kinase stress-signaling pathway in neuronal cells. J. Biol. Chem. 277 (2002) 11465-11472
14. Heikkila R.E. Differential neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in Swiss-Webster mice from different sources. Eur. J. Pharmacol. 117 (1985) 131-133
15. Hoozemans J.J., Veerhuis R., Janssen I., van Elk E.J., Rozemuller A.J., and Eikelenboom P. The role of cyclo-oxygenase 1 and 2 activity in prostaglandin E(2) secretion by cultured human adult microglia: implications for Alzheimer's disease. Brain Res. 951 (2002) 218-226
16. Hoskins J.A., and Davis L.J. The acute effect on levels of catecholamines and metabolites in brain, of a single dose of MPTP in 8 strains of mice. Neuropharmacology 28 (1989) 1389-1397
17. Hunot S., and Hirsch E.C. Neuroinflammatory processes in Parkinson's disease. Ann. Neurol. 53 Suppl 3 (2003) S49-S58
18. Hunot S., Vila M., Teismann P., Davis R.J., Hirsch E.C., Przedborski S., Rakic P., and Flavell R.A. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 665-670
19. Jackson-Lewis V., Jakowec M., Burke R.E., and Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4 (1995) 257-269
20. Javitch J.A., D'Amato R.J., Strittmatter S.M., and Snyder S.H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. U. S. A. 82 (1985) 2173-2177
21. Kupsch A., Sautter J., Gotz M.E., Breithaupt W., Schwarz J., Youdim M.B., Riederer P., Gerlach M., and Oertel W.H. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. J. Neural Transm. 108 (2001) 985-1009
22. Madrigal J.L., Garcia-Bueno B., Moro M.A., Lizasoain I., Lorenzo P., and Leza J.C. Relationship between cyclooxygenase-2 and nitric oxide synthase-2 in rat cortex after stress. Eur. J. Neurosci. 18 (2003) 1701-1705
23. Menegon A., Board P.G., Blackburn A.C., Mellick G.D., and Le Couteur D.G. Parkinson's disease, pesticides, and glutathione transferase polymorphisms. Lancet 352 (1998) 1344-1346
24. Mizuno Y., Sone N., and Saitoh T. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion on activities of the enzymes in the electron transport system in mouse brain. J. Neurochem. 48 (1987) 1787-1793
25. Monaco R., Friedman F.K., Hyde M.J., Chen J.M., Manolatus S., Adler V., Ronai Z., Koslosky W., and Pincus M.R. Identification of a glutathione-S-transferase effector domain for inhibition of jun kinase, by molecular dynamics. J. Protein Chem. 18 (1999) 859-866
26. Muthane U., Ramsay K.A., Jiang H., Jackson-Lewis V., Donaldson D., Fernando S., Ferreira M., and Przedborski S. Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice. Exp. Neurol. 126 (1994) 195-204
27. + and mitochondrial function. Life Sci. 40 (1987) 721-729
28. Nishi K. Expression of c-Jun in dopaminergic neurons of the substantia nigra in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice. Brain Res. 771 (1997) 133-141
29. Nussbaum R.L., and Polymeropoulos M.H. Genetics of Parkinson's disease. Hum. Mol. Genet. 6 (1997) 1687-1692
30. Olanow C.W., and Tatton W.G. Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 22 (1999) 123-144
31. Peng J., Mao X.O., Stevenson F.F., Hsu M., and Andersen J.K. The herbicide paraquat induces dopaminergic nigral apoptosis through sustained activation of the JNK pathway. J. Biol. Chem. 279 (2004) 32626-32632
32. Przedborski S., and Vila M. The last decade in Parkinson's disease research. Basic sciences. Adv. Neurol. 86 (2001) 177-186
33. +. Neurosci. Lett. 75 (1987) 323-328
34. Schauwecker P.E. Seizure-induced neuronal death is associated with induction of c-Jun N-terminal kinase and is dependent on genetic background. Brain Res. 884 (2000) 116-128
35. Sedelis M., Hofele K., Auburger G.W., Morgan S., Huston J.P., and Schwarting R.K. MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behav. Genet. 30 (2000) 171-182
36. Smeyne R.J., and Jackson-Lewis V. The MPTP model of Parkinson's disease. Mol. Brain Res. 134 (2005) 57-66
37. Smeyne M., Jiao Y., Shepherd K.R., and Smeyne R.J. Glia cell number modulates sensitivity to MPTP in mice. Glia 52 (2005) 144-152
38. Smeyne M., Boyd J., Raviie Shepherd K., Jiao Y., Pond B.B., Hatler M., Wolf R., Henderson C., and Smeyne R.J. GSTpi expression mediates dopaminergic neuron sensitivity in experimental parkinsonism. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 1977-1982
39. Sonsalla P.K., and Heikkila R.E. Neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and methamphetamine in several strains of mice. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 12 (1988) 345-354
40. Staal R.G.W., and Sonsalla P.K. Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata. JPET 293 (2000) 336-342
41. Staal R.G.W., Hogan K.A., Liang C.L., German D.C., and Sonsalla P.K. In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium. JPET 293 (2000) 329-335
42. Sundstrom E., Stromberg I., Tsutsumi T., Olson L., and Jonsson G. Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice. Brain Res. 405 (1987) 26-38
43. Tanner C.M., and Goldman S.M. Epidemiology of Parkinson's disease. Neurol. Clin. 14 (1996) 317-335
44. Teismann P., Vila M., Choi D.K., Tieu K., Wu D.C., Jackson-Lewis V., and Przedborski S. COX-2 and neurodegeneration in Parkinson's disease. Ann. N.Y. Acad. Sci. 991 (2003) 272-277
45. Teismann P., Tieu K., Choi D.K., Wu D.C., Naini A., Hunot S., Vila M., Jackson-Lewis V., and Przedborski S. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 5473-5478
46. Wang T., Arifoglu P., Ronai Z., and Tew K.D. Glutathione S-transferase P1-1 (GSTP1-1) inhibits c-Jun N-terminal kinase (JNK1) signaling through interaction with the C terminus. J. Biol. Chem. 276 (2001) 20999-21003
47. Wang W., Shi L., Xie Y., Ma C., Li W., Su X., Huang S., Chen R., Zhu Z., Mao Z., Han Y., and Li M. SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson's disease. Neurosci. Res. 48 (2004) 195-202
48. Xia X.G., Harding T., Weller M., Bieneman A., Uney J.B., and Schulz J.B. Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 10433-10438
49. 2-induced cell death via coordinated regulation of stress kinases. Cancer Res. 60 (2000) 4053-4057